patent.fyi
Applications  /  US 2026/0355201
United States Patent Application Publication

US 2026/0355201 A1

Published
Nov 12, 2026
Filed
Oct 27, 2023
Earliest date on the face
Oct 28, 2022
Classification
A61K 31/519
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Poloxamer stabilizes the suspension

What ifWhat if a poloxamer wets and stabilizes the drug particles?
Claim language“and polysorbate 80”

The hydrophobic block of poloxamer 188 adsorbs to the drug particle surface. Its hydrated outer blocks form a steric barrier that limits particle aggregation in water.

1.1Cyclodextrin complexes the drug

What ifWhat if a cyclodextrin holds dissolved drug in an aqueous preparation?
Claim language“and polysorbate 80”

Hydroxypropyl beta-cyclodextrin associates reversibly with hydrophobic portions of the drug through its internal cavity. This association increases the total dissolved drug concentration by holding part of the drug in complexed form.

1.1Polymer matrix holds the drug

What ifWhat if a dry polymer matrix maintains the drug in an amorphous dispersion?
Claim language“and polysorbate 80”

Spray drying a solution of the drug and copovidone produces a solid dispersion. The polymer reduces molecular mobility in the dry powder and slows crystal growth during storage.

1.1Cellulose polymer slows settling

What ifWhat if a cellulose polymer keeps micronized drug particles suspended by increasing liquid viscosity?
Claim language“and polysorbate 80”

High-shear mixing distributes micronized drug particles in water containing hydrated hydroxypropyl methylcellulose. The higher viscosity slows sedimentation, and shaking redistributes particles that settle.

1.1Neutral crystalline drug form

What ifWhat if the active ingredient is the neutral crystalline compound?
Claim language“a pharmaceutically acceptable salt thereof”

Controlled crystallization isolates the neutral compound as a solid. Milling controls the particle size, and polysorbate 80 promotes wetting when the particles are dispersed in water.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Suspension reference for instrument testing

A laboratory instrument test set contains sealed optical cells filled with the aqueous isoquinolinone suspension and a blank cell filled with the polysorbate 80 vehicle. The instrument measures the blank before recording transmitted light through the suspension at a fixed height. A fixture inverts each suspension cell before measurement, and timed readings track the change in optical signal as particles settle.

Component substitution

Poloxamer as the wetting agent

Poloxamer 188 replaces polysorbate 80 as the nonionic wetting agent in the aqueous isoquinolinone suspension. The poloxamer dissolves in the aqueous vehicle before stirring incorporates the active ingredient particles. Its hydrophobic blocks associate with particle surfaces, and its hydrophilic blocks extend into the aqueous phase to limit aggregation.

Parameter or scale variation

Vial fill and headspace variation

A filling line dispenses the same isoquinolinone and polysorbate 80 suspension into identical 10 mL glass vials at fill volumes of 2 mL, 5 mL and 8 mL. The line closes all vials with the same stopper and crimp seal. After storage, a vial inverter runs at 20 revolutions per minute, and the operator counts the revolutions needed to lift visible sediment from the vial base.

Combination with existing systems

Suspension with a closed sampling loop

A sanitary sampling loop connects the lower outlet of a stirred holding vessel to a return port below the liquid surface. A peristaltic pump circulates the isoquinolinone suspension through the loop while the vessel agitator keeps particles dispersed. A valve diverts a sample into a collection vial after three loop volumes have circulated.

Dry suspension with a dual chamber vial

A dual chamber vial stores a freeze-dried preparation of the isoquinolinone active ingredient, polysorbate 80 and trehalose in one chamber and an aqueous diluent in the other. A movable stopper separates the chambers and opens a bypass when the operator presses the actuator. The diluent flows through the bypass, and inversion rehydrates the dry preparation and disperses the active ingredient before withdrawal.

Automated or data-driven variant

Sensor control of suspension filling

A holding vessel contains the aqueous isoquinolinone suspension with polysorbate 80 and feeds a vial filler through a recirculating line. Optical backscatter probes at two heights in the vessel measure differences in suspended solids. A controller adjusts agitator speed and enables filling after the difference between probe readings stays below a preset threshold for a specified interval.

Specific version of a part

Hydrochloride salt formed by crystallization

Hydrochloric acid protonates a basic site on the compound in solution. Controlled crystallization isolates the hydrochloride salt, and the dried solid is blended with a polysorbate 80-containing excipient premix.

Polysorbate solution wets drug powder

Polysorbate 80 is dissolved in a portion of the formulation water, and the drug powder is added under agitation to form a slurry. The slurry is diluted with the remaining vehicle and mixed until the particles are uniformly dispersed.

Cite aspatent.fyi, US 2026/0355201 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355201/, SHA-256 27cc3f97654081a73859ecdc678abfd6520a1a1d957348359180a4db47c2cd89
First published
Permanent addresshttps://patent.fyi/US20260355201/
Content fingerprint (SHA-256)27cc3f97654081a73859ecdc678abfd6520a1a1d957348359180a4db47c2cd89
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi